C R Bard Inc (BCR.N)

BCR.N on New York Stock Exchange

115.67USD
1 Aug 2013
Price Change (% chg)

$1.07 (+0.93%)
Prev Close
$114.60
Open
$114.63
Day's High
$115.95
Day's Low
$114.63
Volume
116,904
Avg. Vol
143,218
52-wk High
$115.95
52-wk Low
$94.11

BCR.N

Chart for BCR.N

About

C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a... (more)

Overall

Beta: 0.39
Market Cap (Mil.): $9,070.99
Shares Outstanding (Mil.): 79.15
Dividend: 0.21
Yield (%): 0.73

Financials

  BCR.N Industry Sector
P/E (TTM): 54.46 27.50 37.76
EPS (TTM): 2.10 -- --
ROI: 5.40 9.26 18.76
ROE: 10.44 12.54 19.59
Search Stocks

Deals of the day -- mergers and acquisitions

June 28 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

28 Jun 2013

Boston Sci to buy Bard electrophysiology unit for $275 mln

WASHINGTON, June 28 - Medical device maker Boston Scientific Corp said on Friday it would buy the electrophysiology (EP) business of C.R. Bard Inc for $275 million in cash, expanding its roster of products that help treat patients with an abnormal heartbeat.

28 Jun 2013

C R Bard to pay $48 million to settle kickback allegations, DOJ says

- Medical device maker C.R. Bard Inc will pay about $48.3 million to resolve allegations it made illegal payments to hospitals and physicians to entice them to buy its radiation treatment for prostate cancer, the Justice Department said.

13 May 2013

C R Bard to pay $48 mln to settle kickback allegations, DOJ says

May 13 - Medical device maker C.R. Bard Inc will pay about $48.3 million to resolve allegations it made illegal payments to hospitals and physicians to entice them to buy its radiation treatment for prostate cancer, the Justice Department said.

13 May 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Stock Traders Daily
$495.00
Provider: MacroRisk Analytics/EconomicInvestor
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks